Pathogenic RET alterations, including mutations and fusions, drive oncogenesis, most notably medullary and papillary thyroid carcinomas and non-small cell lung cancer, by constitutively activating downstream RAS-MAPK, PI3K-AKT, and JAK-STAT signaling. This evidence concerns the gene RET and non-small cell lung carcinoma.